Article summary
Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being tested, as Gilgamesh Pharmaceuticals moves to challenge Enveric’s patent claims, just weeks after AbbVie announced its $1.2 billion acquisition of Gilgamesh’s lead compound, Bretisilocin (GM-2505). The post The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch appeared first on Microdose.
Continue to the original publication for the complete article.